Table 2 Differences in PFS benefits of Immunotherapy in NSCLC and SCLC by subgroups
From: The landscape of immune checkpoint inhibitor therapy in advanced lung cancer
Variable | Study | Test for Difference | |||
|---|---|---|---|---|---|
NSCLC | SCLC | χ2 | P Value | ||
Overall | 41 | 0.74 [0.67; 0.80] | 0.95 [0.77; 1.13] | 5.03 | 0.02 |
Sex | |||||
 Male | 18 | 0.63 [0.56; 0.69] | 0.87 [0.64; 1.10] | 3.16 | 0.08 |
 Female | 18 | 0.69 [0.57; 0.82] | 0.59 [0.37; 0.81] | 0.67 | 0.41 |
Age | |||||
  < 65 yr | 18 | 0.62 [0.54; 0.70] | 0.76 [0.54; 0.98] | 1.40 | 0.24 |
  ≥ 65 yr | 14 | 0.67 [0.58; 0.77] | 0.76 [0.53; 0.99] | 0.44 | 0.51 |
Line of therapy | |||||
 First | 26 | 0.68 [0.60; 0.76] | 0.83 [0.76; 0.90] | 7.68 | 0.01 |
 Subsequent | 15 | 0.83 [0.73; 0.92] | 1.68 [0.90; 2.45] | 4.59 | 0.03 |
Research methodology | |||||
 ICI vs non-ICI | 20 | 0.82 [0.73; 0.91] | 1.68 [0.90; 2.45] | 4.66 | 0.03 |
 ICI + non-ICI vs non-ICI | 21 | 0.63 [0.57; 0.69] | 0.83 [0.76; 0.90] | 15.28 | < 0.01 |
Drug target | |||||
 Anti-PD-1/PD-L1 | 31 | 0.73 [0.56; 0.81] | 1.16 [0.64; 1.68] | 2.61 | 0.11 |
 Anti-CTLA-4 | 6 | 0.84 [0.73; 0.95] | 0.86 [0.76; 0.96] | 0.07 | 0.80 |
 Anti-PD-1/PD-L1 + CTLA-4 | 4 | 0.75 [0.66; 0.83] | 0.84 [0.68; 0.99] | 1.12 | 0.29 |
ECOG PS | |||||
 0 | 17 | 0.64 [0.54; 0.75] | 0.84 [0.53; 1.15] | 1.42 | 0.23 |
 1 | 17 | 0.64 [0.57; 0.71] | 0.72 [0.53; 0.92] | 0.54 | 0.46 |
Trial phase | |||||
 II | 8 | 0.75 [0.59; 0.91] | 1.23 [0.54; 1.91] | 1.17 | 0.18 |
 III | 33 | 0.73 [0.66; 0.81] | 0.92 [0.71; 1.13] | 2.65 | 0.10 |